News & Videos - PORTOLA PHARMACEUTICALS INC. - English

Portola Pharmaceuticals Announces Virtual 2020 Annual Stockholder Meeting PR Newswire SOUTH SAN FRANCISCO, Calif., May 18, 2020 SOUTH SAN FRANCISCO, Calif. , May 18, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of stockholders, employees and other meeting participants, the location and format of its 2020 Annual Stockholder Meeting (the...

U.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa® for Third Year - Reinforcing Breakthrough Innovation and Clinical Value of Andexxa, Proposed Extension Will Support Patient Access by Continuing to Provide Medicare Reimbursement in the Hospital Setting - PR Newswire SOUTH SAN FRANCISCO, Calif., May 14, 2020 SOUTH SAN FRANCISCO, Calif. , May 14, 2020 /PRNewswire/ -- Portola...

Portola Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update - Reached Agreement to be Acquired by Alexion; Transaction Expected to Close in Third Quarter - - Andexxa®/Ondexxya® Global Net Product Revenues of $25.6 Million - PR Newswire SOUTH SAN FRANCISCO, Calif., May 11, 2020 SOUTH SAN FRANCISCO, Calif. , May 11, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today reported financial results for the three months ended March 31,...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Portola Pharmaceuticals, Inc. - PTLA PR Newswire NEW YORK, May 6, 2020 NEW YORK , May 6, 2020 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating Portola Pharmaceuticals, Inc. ("Portola" or the "Company") (NasdaqGS: PTLA) relating to the sale of the Company to Alexion...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Portola Pharmaceuticals, Inc. PR Newswire NEW YORK, May 5, 2020 NEW YORK , May 5, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Portola Pharmaceuticals, Inc. ("PTLA" or the "Company") (NASDAQ: PTLA) in connection with the proposed acquisition of the Company by Alexion Pharmaceuticals, Inc. ("ALXN") (NASDAQ: ALXN). Under the terms of the acquisition...

Portola Pharmaceuticals Cancels First Quarter 2020 Financial Results Webcast and Conference Call Following Agreement to be Acquired by Alexion PR Newswire SOUTH SAN FRANCISCO, Calif., May 5, 2020 SOUTH SAN FRANCISCO, Calif. , May 5, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) (the "Company" or " Portola ") today announced that it is cancelling its webcast and conference call to discuss the Company's financial results for the first quarter ended March 31, 2020 that was...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Portola Pharmaceuticals, Inc. PR Newswire NEW YORK, May 5, 2020 NEW YORK , May 5, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) and its board of directors concerning the proposed acquisition of the company by Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN). Stockholders will receive $18.00 for each share of Portola Pharmaceuticals stock that...

Thinking about buying stock in Portola Pharmaceuticals, Norwegian Cruise Line, Tetra Technologies, Wayfair, or Chegg? PR Newswire NEW YORK, May 5, 2020 NEW YORK , May 5, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PTLA, NCLH, TTI, W, and CHGG. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. PTLA:...

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., May 1, 2020 SOUTH SAN FRANCISCO, Calif. , May 1, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) announced today that on April 30, 2020 , the Compensation Committee of the Board of Directors approved, effective as of April 30, 2020 , the grant to five new employees of (i) inducement stock options to purchase an aggregate of 10,700 shares of common...

Portola Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 11, 2020 PR Newswire SOUTH SAN FRANCISCO, Calif., April 23, 2020 SOUTH SAN FRANCISCO, Calif. , April 23, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended March 31, 2020 , and provide a general business overview, on Monday, May 11, 2020, at 4:30 p.m. ET ( 1:30...

Portola Pharmaceuticals Announces the Establishment of a Permanent J-code for Andexxa by the Centers for Medicare & Medicaid Services, Effective July 1, 2020 PR Newswire SOUTH SAN FRANCISCO, Calif., April 7, 2020 SOUTH SAN FRANCISCO, Calif. , April 7, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that the Centers for Medicare & Medicaid Services (CMS) established a new permanent J-code for Andexxa ® [coagulation factor Xa (recombinant), inactivated-zhzo]...

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., April 1, 2020 SOUTH SAN FRANCISCO, Calif. , April 1, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) announced today that on March 31, 2020 , the Compensation Committee of the Board of Directors approved, effective as of March 31, 2020 , the grant to eight new employees of (i) inducement stock options to purchase an aggregate of 16,100 shares of...

Portola Pharmaceuticals Announces Proactive Steps Supporting Public Health Efforts to Combat Coronavirus (COVID-19) PR Newswire SOUTH SAN FRANCISCO, Calif., March 18, 2020 SOUTH SAN FRANCISCO, Calif. , March 18, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced proactive steps the Company is taking in support of public heath efforts to prevent furtherspread of coronavirus (or COVID-19) around the globe. As this global pandemic evolves rapidly, Portola's first...

Portola Pharmaceuticals Announces Results Demonstrating Andexxa® was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds Real-World Data Support Use of Andexxa Can Improve Outcomes PR Newswire SOUTH SAN FRANCISCO, Calif., March 16, 2020 SOUTH SAN FRANCISCO, Calif. , March 16, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced new data reinforcing the value of Andexxa ® [coagulation factor Xa...

PORTOLA 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Portola Pharmaceuticals, Inc. - PTLA PR Newswire NEW ORLEANS, March 15, 2020 NEW ORLEANS , March 15, 2020 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana , Charles C. Foti, Jr. , remind investors that they have only until March 16, 2020 to file lead...

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until March 16, 2020 to file lead plaintiff applications in securities class action lawsuits against Portola Pharmaceuticals, Inc. (NasdaqGS: PTLA), if they purchased the Company’s securities between January 8, 2019 and February 26, 2020, inclusive (the “Class Period”). These actions are pending in the United States District Court for the...

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Portola Pharmaceuticals Inc. (“Portola” or the Company”) (NASDAQ: PTLA) and certain of its officers, on behalf of shareholders who purchased Portola securities between November 5, 2019 and January 9, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/ptla . This class action seeks to recover damages...

New Data Demonstrates Andexxa® Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors - Analysis Projects Hospital Use of Andexxa with NTAP Reimbursement Can Reduce Cost Per Hospitalization by $5,400 Compared to 4F-PCC - - Data Presented This Week at Emergencies in Medicine Meeting - PR Newswire SOUTH SAN FRANCISCO, Calif., March 5, 2020 SOUTH SAN FRANCISCO, Calif. , March 5, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ®...

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., March 2, 2020 SOUTH SAN FRANCISCO, Calif. , March 2, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) announced today that on February 28, 2020 , the Compensation Committee of the Board of Directors approved, effective as of February 28, 2020 , a grant to Rajiv Patni of (i) inducement stock options to purchase 125,000 shares of common stock, and (ii)...

On February 28, 2020, a class action lawsuit was filed in the United States District Court for the Northern District of California against Portola Pharmaceuticals, Inc. (NASDAQ: PTLA). Federman & Sherwood reminds current and former shareholders of Portola Pharmaceuticals, Inc. that they only have until Monday, March 16, 2020 to move the court for appointment as a lead plaintiff in this case. The Complaint alleges violations of Section 10(b) and Section 20(a) of the Securities Exchange Act, and...